WP
PACB icon

Westmount Partners’s Pacific Biosciences PACB Stock Holding History

Westmount Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,500
Closed -$26.4K – 228
2024
Q3 		$26.4K Hold
15,500
– – 0.01% 225
2024
Q2 		$18.6K Hold
15,500
– – 0.01% 217
2024
Q1 		$58.1K Buy
+15,500
New +$90.8K 0.02% 207

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westmount Partners's PACB Position: Q4 2024 in Review

Westmount Partners sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 15,500 shares — an estimated $26.4K sold.

Westmount Partners first reported a position in PACB in Q1 2024 and held it in 3 quarters. The position peaked at $58.1K in Q1 2024. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Westmount Partners reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Westmount Partners sold 15,500 Pacific Biosciences shares in Q4 2024, an estimated $26.4K.
  • Westmount Partners first reported a position in Pacific Biosciences in Q1 2024 and held it in 3 quarters.
  • Westmount Partners's Pacific Biosciences position peaked at $58.1K in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Westmount Partners's 13F filing for Q4 2024, filed 13 Jan 2025.